User:Mr. Ibrahem/Belatacept

Belatacept, sold under the brand name Nulojix, is a medication used to prevent rejection following a kidney transplant. It is used with corticosteroids and mycophenolic acid. Use in the United Kingdom is not generally recommended. It is given by injection into a vein.

Common side effects include low red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, and low or high potassium. Other side effects may include infections, cancer, and posttransplant lymphoproliferative disorder. It is a recombinant fusion protein which acts as a T cell activation inhibitor.

Belatacept was approved for medical use in the United States and Europe in 2011. In the United Kingdom 250 mg costs the NHS about £355 as of 2021. This amount in the United States is about 930 USD.